异常DNA甲基化与皮肤黑色素瘤侵袭性临床病理特征及不良生存相关
该回顾性观察研究分析了170例原发性黑色素瘤甲醛固定石蜡包埋肿瘤样本中CpG岛甲基化情况,55%的患者检测到一个或多个基因甲基化,最常见为RARB 31%、PTEN 24%、APC 16%、CDH13 16%、ESR1 14%、CDKN2A 6%和RASSF1 5%。异常甲基化与侵袭性临床病理特征相关,且与较差的无病生存和总生存相关。
要点
- 55%的原发性黑色素瘤患者检测到一个或多个基因甲基化。
- 异常甲基化与侵袭性临床病理特征相关。
- Kaplan-Meier分析显示甲基化与较差的无病生存和总生存相关。
核心结论
- 肿瘤抑制基因异常甲基化是黑色素瘤中的常见事件,与侵袭性临床病理特征和较差生存相关。
- 表观遗传改变可能是有用于常规实践的重要预后标志物。
研究设计与样本
- 这是一项回顾性观察研究,纳入170例黑色素瘤甲醛固定石蜡包埋肿瘤样本。
- 采用甲基化特异性多重连接依赖探针扩增分析DNA甲基化,评估甲基化状态与已知体细胞突变及临床病理特征的关系。
主要发现
- 整个队列中55%的患者检测到一个或多个基因甲基化。
- 最常见的甲基化基因:RARB 31%、PTEN 24%、APC 16%、CDH13 16%、ESR1 14%、CDKN2A 6%和RASSF1 5%。
- 异常甲基化与侵袭性临床病理特征相关:年龄较大、Breslow厚度增加、存在核分裂和溃疡、快速生长型黑色素瘤、分期进展和TERT突变。
- Kaplan-Meier生存分析显示甲基化与较差的无病生存和总生存相关。
关键数值与推荐
- 整个队列中55%的患者检测到一个或多个基因甲基化。
- RARB甲基化31%,PTEN甲基化24%,APC甲基化16%,CDH13甲基化16%,ESR1甲基化14%,CDKN2A甲基化6%,RASSF1甲基化5%。
临床怎么用
- 表观遗传改变可能是有用于常规实践的重要预后标志物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Promoter methylation of tumour suppressor genes (TSGs) has recently been implicated in the pathogenesis of several types of cancer. Regarding melanoma, over 100 genes that contribute to its pathogenesis have been identified to be aberrantly hypermethylated. OBJECTIVES: This is a retrospective observational study that aims to analyse the prevalence of CpG island methylation in a series of primary melanomas, to identify the associations with the main clinicopathological features, and to explore the prognostic significance of methylation in melanoma survival. MATERIALS AND METHODS: DNA methylation was analysed using methylation-specific multiplex ligation-dependent probe amplification in a series of 170 melanoma formalin-fixed paraffin-embedded tumour samples. The relationship between the methylation status, known somatic mutations and clinicopathological features was evaluated. Disease-free survival (DFS) and overall survival (OS) were displayed by the Kaplan-Meier method. RESULTS: In the entire cohort, one or more genes were detected to be methylated in 55% of the patients. The most prevalent methylated genes were RARB 31%, PTEN 24%, APC 16%, CDH13 16%, ESR1 14%, CDKN2A 6% and RASSF1 5%. An association between aberrant methylation and aggressive clinicopathological features was observed (older age, increased Breslow thickness, presence of mitosis and ulceration, fast-growing melanomas, advancing stage and TERT mutations). Furthermore, Kaplan-Meier survival analysis showed a correlation of methylation and poorer DFS and OS. CONCLUSIONS: Aberrant methylation of TSGs is a frequent event in melanoma. It is associated with aggressive clinicopathological features and poorer survival. Epigenetic alterations may represent a significant prognostic marker with utility in routine practice.
引用
- de Unamuno Bustos B, Murria Estal R, Pérez Simó G, et al. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma. Br J Dermatol. 2018. PMID: 29278418. doi:10.1111/bjd.16254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。